Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
This non-inferiority trial finds that rituximab therapy was not inferior to daily cyclophosphamide treatment for induction of remission in severe ANCA-associated vasculitis and may be superior in relapsing disease.
See the associated editorial.
See the associated editorial.
Related Articles:
- Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis
- Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody—associated vasculitis.
- A Randomized, Doubleblind, Placebo-Controlled, Study of Single-Dose Rituximab as Induction in Renal Transplantation
Recent Comments